Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2025-10-30EMA Refused: Syfovre — Apellis Europe B.V.
The EMA refused to grant marketing authorization for Syfovre (pegcetacoplan) for geographic atrophy associated with age-related macular dege…
-
EMA withdrawal · 2025-02-04EMA Application withdrawn: Izelvay (avacincaptad pegol) — Astellas Pharma Europe B.V.
EMA has withdrawn the marketing authorization application for Izelvay (avacincaptad pegol) submitted by Astellas Pharma Europe B.V. for geog…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial evaluating CNTO 2476 for visual acuity impairment due to geographic atrophy from age-related macular degeneration has been wit…
-
CLINICAL_TRIALS withdrawal · 2024-05-30Clinical Trial Update: Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration [Phase 2]
Phase 2 trial evaluating bevacizumab in combination with photodynamic therapy for neovascular age-related macular degeneration was terminate…
-
CLINICAL_TRIALS withdrawal · 2024-03-22Clinical Trial Update: Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy [Phase 4]
A Phase 4 trial evaluating OCTA-directed PDT triple therapy for exudative age-related macular degeneration has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-01-31Clinical Trial Update: The Avastin vs Visudyne for Neovascular AMD Study [Phase 3]
A Phase 3 trial comparing Avastin to Visudyne for neovascular age-related macular degeneration was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-09-23Clinical Trial Update: Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) [Phase 3]
Phase 3 trial evaluating brolucizumab 6mg in a treat-and-extend regimen for neovascular age-related macular degeneration with prior anti-VEG…
-
EMA withdrawal · 2020-10-21EMA Application withdrawn: Rayoqta (abicipar pegol) — Allergan Pharmaceuticals International Limited
The EMA withdrew the application for Rayoqta (abicipar pegol) by Allergan for macular degeneration.
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself [Phase 2]
A Phase 2 trial for a second-line therapy in age-related macular degeneration patients not responding to Lucentis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-26Clinical Trial Update: Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD [Phase 2]
A Phase 2 study evaluating sub-retinal transplantation of retinal pigment epithelial cells for dry age-related macular degeneration has been…
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: Effects of Sun Filters on Age-related Macular Degeneration in People With Lens Implants
A clinical trial investigating the effects of sun filters on age-related macular degeneration in people with lens implants has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2017-04-27Clinical Trial Update: Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 trial of squalamine lactate ophthalmic solution (0.2%) for neovascular age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-02-08Clinical Trial Update: Use of Self-management Group to Improve Quality of Life in Patients With Low Vision [NA]
The clinical trial examining a self-management group to improve quality of life in patients with age-related macular degeneration has been w…
-
CLINICAL_TRIALS withdrawal · 2016-09-21Clinical Trial Update: Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The clinical trial comparing a home macular perimeter with OCT for assessing visual field defects in choroidal neovascularization has been w…
-
CLINICAL_TRIALS withdrawal · 2016-08-08Clinical Trial Update: Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) [Phase 1]
A Phase 1 trial evaluating subretinal Lucentis (ranibizumab) for hemorrhagic age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-03-29Clinical Trial Update: HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration [Phase 2]
The Phase 2 HiPED trial evaluating high-dose ranibizumab (Lucentis) for persistent pigment epithelial detachments in age-related macular deg…
-
CLINICAL_TRIALS withdrawal · 2015-12-31Clinical Trial Update: Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [Phase 1]
Phase 1 trial evaluating imatinib mesylate with intravitreal ranibizumab for choroidal neovascularization due to age-related macular degener…
-
CLINICAL_TRIALS withdrawal · 2015-07-07Clinical Trial Update: Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration [Phase 1]
Phase 1 clinical trial evaluating the combination of efalizumab and intravitreal ranibizumab for age-related macular degeneration was withdr…
-
CLINICAL_TRIALS withdrawal · 2015-04-08Clinical Trial Update: Risk Factors for Drusen Progression
A clinical trial investigating risk factors for drusen progression in age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-06Clinical Trial Update: Investigating Optical and Neural Causes of Vision Loss
A clinical trial investigating optical and neural causes of vision loss related to macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) [Phase 3]
A Phase 3 trial evaluating the combination of Bevasiranib and Lucentis for wet age-related macular degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-12-11Clinical Trial Update: Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration [NA]
The WA-NG Telescope Prosthesis trial for end-stage Age-related Macular Degeneration has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-11-21Clinical Trial Update: Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)? [NA]
This clinical trial examining whether VEGF or CFH gene polymorphisms influence response to VEGF inhibitors in choroidal neovascularization a…
-
CLINICAL_TRIALS withdrawal · 2012-05-10Clinical Trial Update: Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD) [NA]
A pilot trial evaluating reduced-fluence photodynamic therapy with Visudyne plus ranibizumab versus ranibizumab alone for exudative age-rela…
-
CLINICAL_TRIALS withdrawal · 2011-12-30Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) [NA]
A clinical trial evaluating IRay for wet age-related macular degeneration with recurrent leakage due to choroidal neovascularization has bee…